Profile data is unavailable for this security.
About the company
Silence Therapeutics plc is a United Kingdom-based biotechnology company. The Company is developing medicines by harnessing the body's natural mechanism of RNA interference, or RNAi, to inhibit the expression of specific target genes. The Company's mRNAi GOLD (GalNAc Oligonucleotide Discovery) platform can be used to create siRNAs (short interfering RNAs) that precisely target and silence disease-associated genes in the liver. Its wholly owned product candidates include zerlasiran (SLN360), which is designed to address the high and prevalent unmet medical need in reducing cardiovascular risk in people born with high levels of lipoprotein (a), and SLN124, which is designed to address hematological diseases. It also maintains ongoing research and development collaborations with AstraZeneca, Mallinckrodt Pharmaceuticals and Hansoh Pharma, among others. These collaborations collectively represent up to 16 pipeline programs. Its other pipeline products include SLN-HAN-1 and SLN-HAN-2.
- Revenue in USD (TTM)33.64m
- Net income in USD-44.51m
- Incorporated1994
- Employees115.00
- LocationSilence Therapeutics PLC72 Hammersmith RoadLONDON W14 8THUnited KingdomGBR
- Phone+44 203 457 6900
- Fax+44 795 731 8494
- Websitehttps://www.silence-therapeutics.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| USANA Health Sciences, Inc. | 900.45m | 61.94m | 906.81m | 1.80k | 14.86 | 1.81 | 12.17 | 1.01 | 3.20 | 3.20 | 46.56 | 26.25 | 1.46 | 2.73 | -- | 500,250.00 | 10.03 | 16.23 | 12.49 | 21.75 | 80.98 | 81.42 | 6.88 | 8.96 | 3.20 | -- | 0.0026 | 0.00 | -7.77 | -4.98 | -8.02 | -12.76 | 4.86 | -- |
| Nurix Therapeutics Inc | 80.89m | -144.73m | 934.03m | 284.00 | -- | 4.59 | -- | 11.55 | -2.65 | -2.65 | 1.48 | 3.43 | 0.2369 | -- | -- | 284,813.40 | -42.39 | -33.01 | -54.58 | -39.66 | -- | -- | -178.93 | -260.65 | -- | -- | 0.00 | -- | 99.31 | 15.50 | 20.19 | -- | 39.42 | -- |
| OPKO Health Inc | 799.60m | -252.43m | 954.88m | 3.93k | -- | 0.7622 | -- | 1.19 | -0.3427 | -0.3427 | 1.08 | 1.80 | 0.3859 | 7.53 | 6.87 | 203,461.30 | -12.18 | -7.14 | -13.58 | -8.14 | 32.63 | 34.42 | -31.56 | -13.83 | 1.58 | -4.96 | 0.2217 | -- | -14.01 | -2.70 | 42.49 | -- | -10.19 | -- |
| Arcutis Biotherapeutics Inc | 106.39m | -217.42m | 967.79m | 296.00 | -- | 4.29 | -- | 9.10 | -2.91 | -2.91 | 1.30 | 1.95 | 0.248 | 0.6845 | 4.26 | 359,439.20 | -50.68 | -65.64 | -56.21 | -71.72 | 92.99 | -- | -204.36 | -1,513.03 | 9.61 | -6.52 | 0.4741 | -- | 1,517.09 | -- | 15.83 | -- | -- | -- |
| Gyre Therapeutics Inc | 140.62m | -85.66m | 971.39m | 593.00 | -- | 17.13 | -- | 6.91 | -1.88 | -1.88 | 1.55 | 0.663 | 2.00 | -- | 13.75 | 237,136.60 | -107.71 | -73.59 | -184.22 | -99.94 | 96.01 | -- | -53.91 | -205.62 | 2.97 | -- | 0.00 | -- | 14,188.41 | 616.69 | -1,027.55 | -- | 86.95 | -- |
| Silence Therapeutics plc | 33.64m | -44.51m | 979.39m | 115.00 | -- | 6.72 | -- | 29.11 | -0.3911 | -0.3911 | 0.2856 | 1.13 | 0.1829 | -- | 5.37 | 292,521.00 | -24.20 | -43.60 | -27.21 | -54.91 | 69.72 | -- | -132.31 | -287.30 | -- | -- | 0.0022 | -- | 44.99 | -- | -6.86 | -- | 156.10 | -- |
| Liquidia Corp | 15.97m | -107.69m | 983.05m | 136.00 | -- | 11.38 | -- | 61.57 | -1.57 | -1.57 | 0.2359 | 1.13 | 0.098 | -- | 4.77 | 117,404.40 | -66.06 | -55.02 | -72.44 | -62.69 | 76.82 | 82.18 | -674.42 | -474.59 | 7.50 | -28.61 | 0.4944 | -- | 9.75 | 45.23 | -91.40 | -- | 66.93 | -- |
| Innoviva Inc | 311.59m | 181.39m | 986.00m | 112.00 | 7.21 | 1.41 | 4.49 | 3.16 | 2.19 | 2.19 | 3.88 | 11.21 | 0.2599 | 0.9935 | 4.10 | 2,782,054.00 | 15.13 | 26.24 | 15.57 | 28.53 | 86.12 | -- | 58.21 | 76.84 | 9.17 | -- | 0.3883 | -- | -6.30 | 3.53 | -15.99 | -14.57 | -- | -- |
| Ironwood Pharmaceuticals, Inc. | 413.55m | -1.05bn | 1.00bn | 267.00 | -- | -- | -- | 2.42 | -6.79 | -6.79 | 2.52 | -2.08 | 0.5189 | -- | 4.41 | 1,548,880.00 | -135.68 | -4.54 | -164.13 | -5.20 | -- | -- | -261.50 | -7.81 | -- | 8.27 | 1.96 | -- | 7.83 | 5.02 | -672.50 | -- | 160.10 | -- |
| Pharvaris NV | 0.00 | -115.20m | 1.02bn | 82.00 | -- | 2.62 | -- | -- | -2.58 | -2.58 | 0.00 | 7.24 | 0.00 | -- | -- | 0.00 | -40.45 | -36.09 | -43.50 | -38.27 | -- | -- | -- | -- | -- | -127.47 | 0.0005 | -- | -- | -- | -32.15 | -- | -- | -- |
| Arcturus Therapeutics Holdings Inc | 124.53m | -107.30m | 1.05bn | 180.00 | -- | 3.96 | -- | 8.39 | -4.02 | -4.02 | 4.66 | 9.81 | 0.2799 | -- | 2.08 | 691,811.10 | -24.12 | -19.66 | -31.37 | -24.90 | -- | -- | -86.16 | -77.55 | -- | -- | 0.00 | -- | -19.03 | 60.31 | -417.95 | -- | 14.44 | -- |
| Cassava Sciences Inc | 0.00 | -47.90m | 1.06bn | 29.00 | -- | 12.12 | -- | -- | -1.17 | -1.17 | 0.00 | 1.82 | 0.00 | -- | -- | 0.00 | -25.63 | -30.74 | -33.88 | -32.12 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -27.50 | -- | -- | -- |
| Enliven Therapeutics Inc | 0.00 | -79.60m | 1.06bn | 46.00 | -- | 3.32 | -- | -- | -1.93 | -1.93 | 0.00 | 6.79 | 0.00 | -- | -- | 0.00 | -24.66 | -42.26 | -26.11 | -46.62 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -4,910.75 | -- | -- | -- |
| Holder | Shares | % Held |
|---|---|---|
| Invus Public Equities Advisors LLCas of 01 Mar 2024 | 9.00m | 0.00% |
| Bellecapital AGas of 31 Dec 2023 | 2.00 | 0.00% |
| AXA Investment Managers UK Ltd.as of 30 Apr 2024 | 2.00 | 0.00% |
| KLP Kapitalforvaltning ASas of 30 Apr 2024 | 2.00 | 0.00% |
| Harwood Capital LLPas of 31 Mar 2023 | 0.00 | 0.00% |
